Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CDK2 | P24941 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.34 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.34 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.34 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.34 |
| ▸ | PLAT | P00750 | 1/20 | 0.32 |
| ▸ | PKM | P14618 | 1/20 | 0.31 |
| ▸ | MEN1 | O00255 | 1/20 | 0.30 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.30 |
| ▸ | KDM4D | Q6B0I6 | 1/20 | 0.30 |
| ▸ | EPHB3 | P54753 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17821034 | 0.72 | PLAT (0.46) | CDK2ALDH1A1KDM4ESMN1; SMN2L3MBTL1 | |
| SCHEMBL10627204 | 0.69 | CDK2 (0.40) | CDK2ALDH1A1KDM4EPLATPKM | |
| SCHEMBL11303602 | 0.63 | CDK2 (0.53) | CDK2ALDH1A1KDM4EEPHB3 | |
| SCHEMBL1693953 | 0.63 | CDK2 (0.49) | CDK2ALDH1A1KDM4ESMN1; SMN2L3MBTL1 | |
| Hydrochloric Acid SCHEMBL29516534 | 0.61 | CDK2 (0.51) | CDK2ALDH1A1KDM4EEPHB3 | |
| Bromide SCHEMBL29769300 | 0.61 | CDK2 (0.51) | CDK2ALDH1A1KDM4EEPHB3 | |
| SCHEMBL17577082 | 0.61 | CDK2 (0.43) | CDK2ALDH1A1KDM4ESMN1; SMN2L3MBTL1 | |
| SCHEMBL9299039 | 0.61 | CDK2 (0.43) | CDK2ALDH1A1KDM4ESMN1; SMN2L3MBTL1 | |
| Hydrochloric Acid SCHEMBL29572128 | 0.61 | CDK2 (0.47) | CDK2ALDH1A1KDM4ESMN1; SMN2L3MBTL1 | |
| Hydrochloric Acid SCHEMBL29483244 | 0.61 | CDK2 (0.51) | CDK2ALDH1A1KDM4EEPHB3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3774800-B1 | HETEROCYCLIC COMPOUND AND USE THEREOF | TAKEDA PHARMACEUTICALS CO (JP) | 2024-11-13 | — | — | EP | disclosed |
| US-11702419-B2 | Heterocyclic compound and use thereof | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2023-07-18 | — | — | US | disclosed |
| US-20210332053-A1 | HETEROCYCLIC COMPOUND AND USE THEREOF | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2021-10-28 | — | — | US | disclosed |
| CN-111936495-A | Heterocyclic compounds and their use | 武田药品工业株式会社 | 2020-11-13 | — | — | CN | disclosed |
| US-10807987-B2 | Heterocyclic compound and use thereof | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2020-10-20 | — | — | US | disclosed |
| US-20190300536-A1 | HETEROCYCLIC COMPOUND AND USE THEREOF | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2019-10-03 | — | — | US | disclosed |
| US-5302712-A | Intermediates for cephem compounds | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1994-04-12 | — | — | US | disclosed |
| US-5215982-A | Antibiotics | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1993-06-01 | — | — | US | disclosed |
| EP-0427248-A2 | New cephem compounds and processes for preparation thereof | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1991-05-15 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10807987-B2 | Heterocyclic compound and use thereof | GRIN2B, GRIN2A, GRIN2C | CDK2 962/4885ALDH1A1 2709/4885KDM4E 1901/4885 |
| US-20190300536-A1 | HETEROCYCLIC COMPOUND AND USE THEREOF | GRIN2B, GRIN2A, GRIN2C | CDK2 962/4885ALDH1A1 2709/4885KDM4E 1901/4885 |
| US-20210332053-A1 | HETEROCYCLIC COMPOUND AND USE THEREOF | GRIN2B, GRIN2A, GRIN2C | CDK2 962/4885ALDH1A1 2709/4885KDM4E 1901/4885 |
| US-11702419-B2 | Heterocyclic compound and use thereof | GRIN2B, GRIN2A, GRIN2C | CDK2 962/4885ALDH1A1 2709/4885KDM4E 1901/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.